Page 4 - Declan Doogan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Mar 02, 2021   New Board appointments strengthen Tenax with world-class expertise in cardiovascular drug development, commercial strategy, and business development New Directors will provide significant guidance as Tenax is poised to advance its two leading drug candidates into late-stage clinical testing Transformational step as Tenax strengthens its positioning as a leading specialty pharmaceutical company focused on cardio-pulmonary therapeutics   a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases ...

MORRISVILLE –Tenax Therameputics is acquiring an Illinois-based biotech firm with a promising hypertension treatment and named that company’s cofounder as its chief medical officer. Tenax (Nasdaq: TENX) shares soared 38% to $2.45 shortly after the announced deal for PH Precision Med (PHPM) and the appointment of Stuart Rich, MD, as its CMO early Tuesday. Tenax is paying some 12 million shares of stock to PHPM shareholders. PHPM is focused on a potential treatment of pulmonary arterial hypertension, and its lead candidate has received Orphan Drug Designation from the FDA. The drug – a ...

LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million Convertible Debt Financing News provided by Share this article Share this article PITTSBURGH, Dec. 30, 2020 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company developing cell therapies that enable organ regeneration, announced today that the U.S Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application. Under the IND, LyGenesis will be conducting a Phase 2a study on the safety, tolerability, and efficacy...